Invention Effect of Xuesaitong for Coronary Heart Disease Unstable Angina with Blood Stasis and Relevant microRNA

WANG Jie; TENG Fei; LIU Yong-mei; CHEN Guang

doi:10.13422/j.cnki.syfjx.2017190011

您当前的位置：

首页 >

文章列表页 >

Invention Effect of Xuesaitong for Coronary Heart Disease Unstable Angina with Blood Stasis and Relevant microRNA

更新时间：2024-01-04

- Invention Effect of Xuesaitong for Coronary Heart Disease Unstable Angina with Blood Stasis and Relevant microRNA
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 23, Issue 19, Pages: 11-16(2017)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.2017190011
  CLC： R259
- Published：2017
- 稿件说明：
移动端阅览
WANG Jie, TENG Fei, LIU Yong-mei, et al. Invention Effect of Xuesaitong for Coronary Heart Disease Unstable Angina with Blood Stasis and Relevant microRNA[J]. Chinese journal of experimental traditional medical formulae, 2017, 23(19): 11-16.
DOI：

WANG Jie, TENG Fei, LIU Yong-mei, et al. Invention Effect of Xuesaitong for Coronary Heart Disease Unstable Angina with Blood Stasis and Relevant microRNA[J]. Chinese journal of experimental traditional medical formulae, 2017, 23(19): 11-16. DOI： 10.13422/j.cnki.syfjx.2017190011.

摘要

目的：观察血塞通（XST）治疗及干预冠心病不稳定型心绞痛血瘀证临床疗效及患者外周血hsa-miR-199a-5p，hsa-miR-146b-5p，KIR3DS1，HLA-DPB1，TP53SESN2，NCR1，PRF1表达的影响，阐述XST治疗冠心病血瘀证可能的分子机制。方法：选取心绞痛分级Ⅰ~Ⅲ级的冠心病不稳定型心绞痛血瘀证患者80例，随机分为对照组和治疗组，各40例。对照组给予常规西药治疗+安慰剂，治疗组在常规西药治疗基础上加用血塞通软胶囊，治疗4周。观察治疗前后患者缺血总负荷、西雅图心绞痛质量评分，血流动力学和血脂指标变化，评估XST治疗冠心病血瘀证的临床疗效。实时荧光定量聚合酶链反应（Real-time polymerase chain reaction，Real-time PCR）检测外周血hsa-miR-199a-5p，hsa-miR-146b-5p，KIR3DS1，HLA-DPB1，TP53，SESN2，NCR1，PRF1等基因表达变化。结果：治疗后与对照组比较，治疗组缺血总负荷降低（P<0.05）；治疗后与对照组比较，治疗组全血黏度、血浆黏度和红细胞刚性指数下降（P<0.05）；治疗后与对照组比较，治疗组甘油三酯（TG），总胆固醇（TC），低密度脂蛋白-胆固醇（LDL-C）降低（P<0.05）；治疗后与对照组比较，治疗组KIR3DS1，TP53，SESN2，PRF1上调，hsa-miR-199a-5p，hsa-miR-146b-5p下调（P<0.05）结论： XST可有效改善冠心病不稳定型心绞痛血瘀证患者症状，其机制可能与调控hsa-miR-199a-5p，hsa-miR-146b-5p相关。

Abstract

Objective: To observe the clinical efficacy of xuesaitong (XST) for coronary heart disease unstable angina with blood stasis

and investigate its effects on expression levels of hsa-miR-199a-5p

hsa-miR-146b-5p

KIR3DS1

HLA-DPB1

TP53SESN2

NCR1

and PRF1 in peripheral blood and to elucidate the molecular mechanism of XST for the coronary heart disease with blood stasis. Method: The 80 patients with coronary heart disease unstable angina grade Ⅰ-Ⅲ with blood stasis were enrolled and randomly divided into treatment group and control group (40 cases in each group). The patients in control group received routine western medicine and placebo

while the patients in treatment group also received XST capsules on the basis of routine western medicine therapy. The treatment duration was 4 weeks for both groups. The levels of total ischemic burden

seattle quality score for angina pectoris

haemo-dynamics and blood lipid were observed before and after treatment to evaluate the clinical of XST capsules for coronary heart disease unstable angina with blood stasis. Besides

hsa-miR-199a-5p

hsa-miR-146b-5p

KIR3DS1

HLA-DPB1

TP53

SESN2

NCR1

and PRF1 were validated by Real-time PCR. Result: As compared with control group

total ischemic burden

whole blood viscosity

plasma viscosity

red blood cell rigidity index

cholesterol (TC)

triglyceride(TG)

and low density lipoprotein cholesterol (LDL-C) were decreased in treatment group (P<0.05) after treatment; KIR3DS1

TP53

SESN2

PRF1 genes were up-regulated significantly while hsa-miR-199a-5p

hsa-miR-146b-5p levels were down-regulated in treatment group (P<0.05). Conclusion: XST could ease the symptoms of patients with coronary heart disease unstable angina with blood stasis and the underlying mechanism might be associated with hsa-miR-199a-5p and hsa-miR-146b-5p.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Establishment and Evaluation of Rat Model of Myocardial Ischemia-reperfusion Injury with Phlegm and Blood Stasis Blocking Collaterals Syndrome Based on Metabolomics

Establishment and Evaluation of Rat Model of Acute Myocardial Infarction in Coronary Heart Disease with Qi and Yin Deficiency Syndrome Based on Sleep Deprivation Combined with Coronary Artery Ligation

Mechanism of Xuefu Zhuyutang in Intervening in Ferroptosis in Rats with Coronary Heart Disease with Blood Stasis Syndrome Based on ACSL4 Signalling Pathway

Construction of an Intelligent Diagnosis and Treatment Ontology for Traditional Chinese Medicine Based on Clinical Practice Guidelines：A Case Study of Coronary Heart Disease

Effect of Yiqi Huoxue Prescription on cAMP/Epac1/Rap1 Signaling Pathway in Coronary Heart Disease Rats with Qi Deficiency and Blood Stasis Syndrome

Related Author

HU Longxiao

GAO Jiabei

MA Weihao

LU Jieming

GAO Yunxiao

YUAN Yue

ZHANG Qiuyan

CHEN Xiaoxiao

Related Institution

Natural History Museum of China

Beijing Key Laboratory of Chinese Materia Pharmacology，National Clinical Research Center of Traditional Chinese Medicine for Cardiovascular Diseases，Institute of Basic Medical Sciences， Xiyuan Hospital，China Academy of Chinese Medical Sciences

School of Clinical Medicine，Beijing University of Chinese Medicine

Institute of Basic Medical Sciences，Xiyuan Hospital，China Academy of Chinese Medical Sciences

Hunan University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰